NASDAQ:ROIV

Roivant Sciences (ROIV) Stock Forecast, Price & News

$9.75

0.00 (0.00%)

(As of 05:21 PM ET)

Compare

Today's Range: $9.64
▼
$9.85
50-Day Range: $7.09
▼
$9.75
52-Week Range: $2.87
▼
$10.00

Volume: 3.92 million shs
Average Volume: 2.87 million shs
Market Capitalization: $7.39 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.80

Roivant Sciences MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 31.8% Upside
$12.80 Price Target
Short Interest: Bearish
3.50% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$100.32 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.78) to ($1.25) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

366th out of 982 stocks

Pharmaceutical Preparations Industry

175th out of 480 stocks

3.5

Analyst's Opinion

Consensus Rating
Roivant Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.80, Roivant Sciences has a forecasted upside of 31.8% from its current price of $9.71.
Amount of Analyst Coverage
Roivant Sciences has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.50% of the float of Roivant Sciences has been sold short.
Short Interest Ratio / Days to Cover
Roivant Sciences has a short interest ratio ("days to cover") of 4.8.
Change versus previous month
Short interest in Roivant Sciences has recently increased by 2.64%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Roivant Sciences does not currently pay a dividend.
Dividend Growth
Roivant Sciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ROIV.

2.9

News and Social Media Coverage

News Sentiment
Roivant Sciences has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Roivant Sciences this week, compared to 3 articles on an average week.
Search Interest
13 people have searched for ROIV on MarketBeat in the last 30 days. This is an increase of 1,200% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Roivant Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Roivant Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $100,320,605.00 in company stock.
Percentage Held by Insiders
13.00% of the stock of Roivant Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
52.66% of the stock of Roivant Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Roivant Sciences are expected to grow in the coming year, from ($1.78) to ($1.25) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Roivant Sciences is -5.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Roivant Sciences is -5.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Roivant Sciences has a P/B Ratio of 3.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Receive ROIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Roivant Sciences and its competitors with MarketBeat's FREE daily newsletter.

ROIV Stock News Headlines

May 27, 2023 | msn.com

Roivant Sciences: Coming Nicely To The Boil With Multiple Opportunities

May 22, 2023 | americanbankingnews.com

Roivant Sciences (NASDAQ:ROIV) PT Raised to $14.00 at JPMorgan Chase & Co.

June 7, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

May 19, 2023 | markets.businessinsider.com

Jefferies Keeps Their Buy Rating on Roivant Sciences (ROIV)

May 18, 2023 | msn.com

JP Morgan Maintains Roivant Sciences (ROIV) Overweight Recommendation

May 17, 2023 | msn.com

HC Wainwright & Co. Maintains Roivant Sciences (ROIV) Buy Recommendation

May 17, 2023 | americanbankingnews.com

Roivant Sciences (NASDAQ:ROIV) Price Target Raised to $15.00 at HC Wainwright

May 17, 2023 | barrons.com

S&P 500 Futures Rise in Premarket Trading; Roivant Sciences, Dynatrace Lead

June 7, 2023 | Legacy Research (Affiliate) (Ad)

Sell Every Stock, Except ONE (Ticker Revealed)

We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.

May 17, 2023 | markets.businessinsider.com

Roivant Sciences (ROIV) Receives a Buy from H.C. Wainwright

May 16, 2023 | msn.com

Marching Towards FDA Approval: Dermavant's Vtama Cream Excels in Phase 3 Trial, Eyes 2024 Submission

May 16, 2023 | msn.com

Roivant stock rises after Vtama meets main goal of 2nd phase 3 eczema study

May 16, 2023 | finance.yahoo.com

Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old

May 15, 2023 | markets.businessinsider.com

Goldman Sachs Keeps Their Buy Rating on Roivant Sciences (ROIV)

May 12, 2023 | yahoo.com

Ohio presidential candidate says U.S. should raise voting age from 18 to 25

May 12, 2023 | msn.com

HC Wainwright & Co. Reiterates Roivant Sciences (ROIV) Buy Recommendation

May 12, 2023 | markets.businessinsider.com

Roivant Sciences (ROIV) Gets a Buy from H.C. Wainwright

May 11, 2023 | bizjournals.com

The Petri Dish: Laronde CEO exits after 6 months; Enanta seeks Covid pill partner

May 11, 2023 | americanbankingnews.com

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $546,569.58 in Stock

May 10, 2023 | americanbankingnews.com

Eric Venker Sells 88,838 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock

May 6, 2023 | americanbankingnews.com

Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) CAO Sells $130,653.14 in Stock

May 4, 2023 | americanbankingnews.com

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 109,074 Shares

May 1, 2023 | americanbankingnews.com

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $625,604.14 in Stock

May 1, 2023 | americanbankingnews.com

Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) CAO Sells $762,364.40 in Stock

April 29, 2023 | americanbankingnews.com

Roivant Sciences Ltd. (NASDAQ:ROIV) CAO Rakhi Kumar Sells 71,989 Shares

April 24, 2023 | barrons.com

S&P 500 Futures Fall in Premarket Trading; Roivant Sciences, DoubleVerify Lead

April 20, 2023 | msn.com

These 2 Growth Stocks Might Be Incredibly Undervalued Right Now

See More Headlines

ROIV Price History

30 days | 90 days | 365 days | Advanced Chart

ROIV Company Calendar

Today: 6/07/2023
Next Earnings (Estimated): 6/27/2023
Fiscal Year End: 3/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ROIV
CUSIP: N/A
CIK: 1635088
Web: roivant.com
Phone: 44-20-7400-3347
Fax: N/A
Employees: 620
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $12.80
High Stock Price Forecast: $15.00
Low Stock Price Forecast: $10.00
Forecasted Upside/Downside: +31.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.78)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-845,260,000.00
Net Margins: -2,887.92%
Pretax Margin: -3,100.36%
Return on Equity: -73.96%
Return on Assets: -51.87%

Debt

Debt-to-Equity Ratio: 0.26
Current Ratio: 6.74
Quick Ratio: 6.74

Sales & Book Value

Annual Sales: $55.29 million
Price / Sales: 134.02
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.93 per share
Price / Book: 3.33

Miscellaneous

Outstanding Shares: 758,430,000
Free Float: 659,831,000
Market Cap: $7.41 billion
Optionable: Not Optionable
Beta: 1.22

Key Executives

Mr. Vivek Ramaswamy (Age 37)
Founder & Chairman
Comp: $1.26M

Mr. Matthew Gline (Age 38)
CEO & Director
Comp: $1.45M

Dr. Eric Venker M.D. (Age 35)
Pharm.D., Pres & COO
Comp: $981.38k

Dr. Mayukh Sukhatme M.D. (Age 46)
Pres & Chief Investment Officer
Comp: $910.19k

Mr. Richard Pulik (Age 43)
Chief Financial Officer

Ms. Rakhi Kumar (Age 42)
Chief Accounting Officer

Dr. Huafeng Xu Ph.D.
Chief Technology Officer

Mr. Josh Chen
Gen. Counsel

Ms. Kelly Graff
Head of People

Ms. Marianne L. Romeo (Age 54)
Head of Global Transactions & Risk Management

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ROIV Stock - Frequently Asked Questions

Should I buy or sell Roivant Sciences stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Roivant Sciences in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ROIV shares.
View ROIV analyst ratings or view top-rated stocks.
What is Roivant Sciences' stock price forecast for 2023?: 5 brokerages have issued 1-year target prices for Roivant Sciences' stock. Their ROIV share price forecasts range from $10.00 to $15.00. On average, they expect the company's stock price to reach $12.80 in the next twelve months. This suggests a possible upside of 31.0% from the stock's current price.
View analysts price targets for ROIV or view top-rated stocks among Wall Street analysts.
How have ROIV shares performed in 2023?: Roivant Sciences' stock was trading at $7.99 at the start of the year. Since then, ROIV stock has increased by 22.3% and is now trading at $9.77.
View the best growth stocks for 2023 here.
When is Roivant Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 27th 2023.
View our ROIV earnings forecast.
What ETFs hold Roivant Sciences' stock?: ETFs with the largest weight of Roivant Sciences (NASDAQ:ROIV) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Direxion Moonshot Innovators ETF (MOON), Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco DWA Momentum ETF (PDP), Invesco Nasdaq Biotechnology ETF (IBBQ) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).
What is Roivant Sciences' stock symbol?: Roivant Sciences trades on the NASDAQ under the ticker symbol "ROIV."

Who are Roivant Sciences' major shareholders?: Roivant Sciences' stock is owned by a number of retail and institutional investors. Top institutional investors include SB Investment Advisers UK Ltd. (10.95%), FMR LLC (4.06%), Wellington Management Group LLP (1.59%), State Street Corp (1.06%), BlackRock Inc. (0.82%) and Rubric Capital Management LP (0.74%). Insiders that own company stock include Eric Venker, Financial Lp Qvt, Matthew Gline, Pharma Technologies Ltd Dexcel, Rakhi Kumar, Richard Pulik, Sciences Ltd Roivant, Svf Investments (Uk) Ltd and Vivek Ramaswamy.
View institutional ownership trends.
How do I buy shares of Roivant Sciences?: Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Roivant Sciences' stock price today?: One share of ROIV stock can currently be purchased for approximately $9.77.
How much money does Roivant Sciences make?: Roivant Sciences (NASDAQ:ROIV) has a market capitalization of $7.41 billion and generates $55.29 million in revenue each year. The company earns $-845,260,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis.
How many employees does Roivant Sciences have?: The company employs 620 workers across the globe.
How can I contact Roivant Sciences?: Roivant Sciences' mailing address is Clarendon House, 2 Church Street, Hamilton Parish HM 11. The official website for the company is roivant.com. The company can be reached via phone at 44-20-7400-3347.

This page (NASDAQ:ROIV) was last updated on 6/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial